← Back to Events
GENERAL CONCLUDED
6th Annual Thought
Medical affairs and commercial event focused on KOL engagement and speaker program development.
150+ Attendees
Coverage & Analysis
No coverage articles yet. Check back closer to the event.
🇺🇸 Latest Americas News
All news → May 5 Palvella Therapeutics Begins Phase 2 Trial of QTORIN Rapamycin for Rare Angiokeratomas May 5 Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment May 5 CAPLYTA (Lumateperone) Ranks Highest Among FDA-Approved Adjunctive Depression Treatments in Network Meta-Analysis May 5 Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD May 5 Cellenkos Receives FDA Clearance for CK0802 Phase 1b/2a Trial in Steroid-Refractory GVHD